- Home
- BVFL vs YMAB Comparison
BVFL vs YMAB Comparison
Compare BVFL & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- YMAB
- Stock Information
- Founded
- BVFL 1873
- YMAB 2015
- Country
- BVFL United States
- YMAB United States
- Employees
- BVFL N/A
- YMAB N/A
- Industry
- BVFL Savings Institutions
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BVFL Finance
- YMAB Health Care
- Exchange
- BVFL Nasdaq
- YMAB Nasdaq
- Market Cap
- BVFL 160.4M
- YMAB 192.4M
- IPO Year
- BVFL N/A
- YMAB 2018
- Fundamental
- Price
- BVFL $14.27
- YMAB $4.33
- Analyst Decision
- BVFL
- YMAB Buy
- Analyst Count
- BVFL 0
- YMAB 11
- Target Price
- BVFL N/A
- YMAB $17.55
- AVG Volume (30 Days)
- BVFL 40.5K
- YMAB 216.1K
- Earning Date
- BVFL 07-17-2025
- YMAB 08-11-2025
- Dividend Yield
- BVFL N/A
- YMAB N/A
- EPS Growth
- BVFL N/A
- YMAB N/A
- EPS
- BVFL 1.06
- YMAB N/A
- Revenue
- BVFL $38,257,000.00
- YMAB $88,658,000.00
- Revenue This Year
- BVFL N/A
- YMAB N/A
- Revenue Next Year
- BVFL N/A
- YMAB $15.15
- P/E Ratio
- BVFL $13.42
- YMAB N/A
- Revenue Growth
- BVFL 1.89
- YMAB 4.92
- 52 Week Low
- BVFL $11.38
- YMAB $3.55
- 52 Week High
- BVFL $18.19
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- BVFL 29.16
- YMAB 46.67
- Support Level
- BVFL $14.41
- YMAB $4.46
- Resistance Level
- BVFL $15.08
- YMAB $4.98
- Average True Range (ATR)
- BVFL 0.53
- YMAB 0.33
- MACD
- BVFL -0.08
- YMAB -0.05
- Stochastic Oscillator
- BVFL 12.50
- YMAB 7.77
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.